These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 6086220

  • 21. [In vitro evaluation of the activity and interactions of cefotaxime and its metabolite desacetylcefotaxime against strains of enterobacteria, staphylococci and Bacteroides fragilis isolated from hospital infections].
    Pitzus E.
    G Ital Chemioter; 1989; 36(1-3):57-64. PubMed ID: 2488914
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
    Canawati HN.
    Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination.
    Nanetti A, La Placa M.
    J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765
    [Abstract] [Full Text] [Related]

  • 32. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R, Gutmann L, Kitzis MD, Goldstein F, Acar JF.
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [Abstract] [Full Text] [Related]

  • 33. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF, Wildfeuer A.
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The in vitro antimicrobial activity of desacetylcefotaxime compared to other related beta-lactams.
    Schrinner E, Limbert M, Seeger K, Seibert G, Novick WJ.
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):13S-20S. PubMed ID: 6086214
    [Abstract] [Full Text] [Related]

  • 36. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
    Devlin HR, Boskovski L.
    Drugs; 1988 Jun; 35 Suppl 2():45-50. PubMed ID: 3396488
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Antibacterial activity of cefotaxime, desacetylcefotaxime, and the combination of the two.
    Friis H.
    Diagn Microbiol Infect Dis; 1989 Jun; 12(1):67-72. PubMed ID: 2714074
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.
    Höffken G, Lode H, Koeppe P, Ruhnke M, Borner K.
    Chemotherapy; 1984 Jun; 30(1):7-17. PubMed ID: 6319092
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.